[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"abrasion\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:abrasion":46},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":5},"100642324",false,"NCT07642973","A Study to Evaluate the Safety and Clinical Performance of a Dexpanthenol Medicated Hydrogel Patch in the Treatment of Standardized Superficial Abrasions","A Randomized, Single-Blind, Intra-Individual Controlled Study to Evaluate the Safety and Clinical Performance of a Dexpanthenol Medicated Hydrogel Patch in the Treatment of Standardized Superficial Abrasions","Dexpanthenol","Inclusion Criteria:\n\n* Healthy male or female volunteers aged 18 to 64 years (inclusive).\n* Informed consent form signed voluntarily before any study-related procedure.\n* Subjects willing and able to comply with all study protocol requirements, including scheduled visits and home-wear restrictions.\n* Intact, healthy skin on both volar forearms (free of tattoos, scars, sunburns, or active skin lesions in the designated test areas).\n* Agree to take precautions to prevent pregnancy (applicable only to non-menopausal women), including abstinence, intrauterine devices (IUDs), progestogen implants, combined estrogenic-progestogen contraceptives, the use of condoms;\n\nExclusion Criteria:\n\n* Known hypersensitivity or allergy to Dexpanthenol, hydrogel components, acrylic adhesives, or any component of the investigational devices.\n* History of keloid formation, hypertrophic scarring, or abnormal wound healing.\n* Active dermatological conditions (e.g., psoriasis, eczema, atopic dermatitis, active infections) on the upper extremities.\n* History of diabetes mellitus, peripheral vascular disease, or arterial\u002Fvenous microangiopathy.\n* Systemic treatment with corticosteroids, immunosuppressive drugs, Anticoagulants, antiplatelet agents or cytostatic agents within 4 weeks prior to Baseline, or anticipated need during the study.\n* Topical treatment (steroids, retinoids, antibiotics, or moisturizers) applied to the volar forearms within 2 weeks prior to Baseline.\n* Active heavy smokers (more than 10 cigarettes per day) or users of nicotine-replacement therapies (nicotine alters cutaneous microcirculation and significantly impairs wound healing kinetics)\n* Pregnant or lactating women, or women of childbearing potential not using highly effective contraception (see inclusion criteria).\n* Not willing and able to comply with all study protocol requirements",true,"ALL","18 Years","64 Years",{"count":21,"type":22},40,"ESTIMATED","INTERVENTIONAL",[25],"NA","Clinical evaluation of a Dexpanthenol-medicated wound plaster on standardized superficial skin abrasions",[28,29],"Skin Wounds","Abrasion",[31,32,33],"superficial wounds","dexpanthenol","plaster","NOT_YET_RECRUITING","2026-06-12",{"date":37,"type":38},"2026-06-16","ACTUAL",{"date":40,"type":22},"2026-09",{"date":42,"type":22},"2026-12",{"name":44,"class":45},"Wooshin Labottach Co., Ltd.","INDUSTRY",""]